$RKDA
Arcadia Biosciences, Inc.

2016 Q1 Form 10-Q Financial Statement

#000156459016018994 Filed on May 10, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2015 Q1
Revenue $852.0K $815.0K
YoY Change 4.54% -40.81%
Cost Of Revenue $147.0K $56.00K
YoY Change 162.5% -38.46%
Gross Profit $705.0K $759.0K
YoY Change -7.11% -40.98%
Gross Profit Margin 82.75% 93.13%
Selling, General & Admin $3.436M $2.638M
YoY Change 30.25% 39.95%
% of Gross Profit 487.38% 347.56%
Research & Development $2.202M $1.832M
YoY Change 20.2% -7.61%
% of Gross Profit 312.34% 241.37%
Depreciation & Amortization $70.00K $70.00K
YoY Change 0.0% -22.22%
% of Gross Profit 9.93% 9.22%
Operating Expenses $5.785M $4.526M
YoY Change 27.82% 14.32%
Operating Profit -$4.933M -$3.711M
YoY Change 32.93% 43.73%
Interest Expense $327.0K $467.0K
YoY Change -29.98% 21.61%
% of Operating Profit
Other Income/Expense, Net $76.00K -$1.396M
YoY Change -105.44% 6547.62%
Pretax Income -$5.184M -$5.574M
YoY Change -7.0% 86.61%
Income Tax $10.00K $229.0K
% Of Pretax Income
Net Earnings -$5.190M -$5.803M
YoY Change -10.56% 66.94%
Net Earnings / Revenue -609.15% -712.02%
Basic Earnings Per Share
Diluted Earnings Per Share -$2.348M -$2.661M
COMMON SHARES
Basic Shares Outstanding 44.22M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q1 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $50.19M $11.28M
YoY Change 344.95%
Cash & Equivalents $29.54M $11.28M
Short-Term Investments $20.65M
Other Short-Term Assets $1.330M $250.0K
YoY Change 432.0%
Inventory $320.0K $521.0K
Prepaid Expenses
Receivables $690.0K $150.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $52.54M $12.37M
YoY Change 324.63%
LONG-TERM ASSETS
Property, Plant & Equipment $660.0K $663.0K
YoY Change -0.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $14.91M $500.0K
YoY Change 2882.0%
Other Assets $2.010M $3.783M
YoY Change -46.87%
Total Long-Term Assets $17.57M $7.047M
YoY Change 149.33%
TOTAL ASSETS
Total Short-Term Assets $52.54M $12.37M
Total Long-Term Assets $17.57M $7.047M
Total Assets $70.11M $19.42M
YoY Change 261.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.00K $80.00K
YoY Change -87.5%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $4.360M
YoY Change -100.0%
Long-Term Debt Due $1.082M
YoY Change
Total Short-Term Liabilities $4.160M $12.06M
YoY Change -65.49%
LONG-TERM LIABILITIES
Long-Term Debt $24.98M $8.588M
YoY Change 190.85%
Other Long-Term Liabilities $5.490M $3.000M
YoY Change 83.0%
Total Long-Term Liabilities $24.98M $26.72M
YoY Change -6.52%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.160M $12.06M
Total Long-Term Liabilities $24.98M $26.72M
Total Liabilities $34.63M $38.78M
YoY Change -10.69%
SHAREHOLDERS EQUITY
Retained Earnings -$119.8M
YoY Change
Common Stock $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $35.48M -$91.88M
YoY Change
Total Liabilities & Shareholders Equity $70.11M $19.42M
YoY Change 261.02%

Cashflow Statement

Concept 2016 Q1 2015 Q1
OPERATING ACTIVITIES
Net Income -$5.190M -$5.803M
YoY Change -10.56% 66.94%
Depreciation, Depletion And Amortization $70.00K $70.00K
YoY Change 0.0% -22.22%
Cash From Operating Activities -$4.860M -$2.600M
YoY Change 86.92% 22.07%
INVESTING ACTIVITIES
Capital Expenditures $137.0K $7.000K
YoY Change 1857.14%
Acquisitions
YoY Change
Other Investing Activities $10.47M $0.00
YoY Change -100.0%
Cash From Investing Activities $10.33M -$10.00K
YoY Change -103400.0% -98.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.000K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 90.00K -2.690M
YoY Change -103.35% -627.45%
NET CHANGE
Cash From Operating Activities -4.860M -2.600M
Cash From Investing Activities 10.33M -10.00K
Cash From Financing Activities 90.00K -2.690M
Net Change In Cash 5.560M -5.300M
YoY Change -204.91% 128.45%
FREE CASH FLOW
Cash From Operating Activities -$4.860M -$2.600M
Capital Expenditures $137.0K $7.000K
Free Cash Flow -$4.997M -$2.607M
YoY Change 91.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44215156
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
84000
CY2016Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
84000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7695000
CY2015Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1695000
CY2015Q1 rkda Deemed Dividends Warrant
DeemedDividendsWarrant
197000
CY2016Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5190000
CY2015Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7695000
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.71
CY2016Q1 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
76000
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2075407
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5106000
CY2016Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
23000
CY2015Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
23000
CY2016Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
67000
CY2015Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
72000
CY2015Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1238000
CY2016Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
45000
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2000
CY2015Q1 rkda Payments For Notes Payable And Convertible Promissory Notes
PaymentsForNotesPayableAndConvertiblePromissoryNotes
1452000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
94000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-2688000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
221000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
387000
CY2015Q1 rkda Change In Fair Value Of Derivative Liabilities Related To Convertible Promissory Notes
ChangeInFairValueOfDerivativeLiabilitiesRelatedToConvertiblePromissoryNotes
1399000
CY2016Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
48000
CY2015Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
141000
CY2016Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-119000
CY2015Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-892000
CY2016Q1 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
24000
CY2015Q1 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-210000
CY2016Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-14000
CY2015Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
49000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
641000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-24000
CY2016Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
152000
CY2015Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-8000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
414000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
235000
CY2016Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-7000
CY2015Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
22000
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
200000
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-136000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4855000
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2598000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
137000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5567000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5293000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16571000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11278000
CY2016Q1 us-gaap Interest Paid
InterestPaid
193000
CY2015Q1 us-gaap Interest Paid
InterestPaid
510000
CY2016Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
1000
CY2015Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
148000
CY2015Q1 rkda Accretion Of Redeemable Convertible Preferred Stock
AccretionOfRedeemableConvertiblePreferredStock
1695000
CY2015Q1 rkda Deferred Stock Offering Costs Included In Accounts Payable And Accrued Liabilities
DeferredStockOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities
-264000
CY2016Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1000
CY2015Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
24930000
CY2016Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
197000
CY2016Q1 rkda Number Of Equity Incentive Plans
NumberOfEquityIncentivePlans
2
CY2016Q1 dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Arizona
CY2016Q1 rkda Entity Incorporation Year Of Incorporation
EntityIncorporationYearOfIncorporation
2002
CY2016Q1 rkda Entity Reincorporation State Country Name
EntityReincorporationStateCountryName
Delaware
CY2016Q1 rkda Entity Reincorporation Date Of Reincorporation
EntityReincorporationDateOfReincorporation
2015-03
CY2016Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-four
CY2016Q1 us-gaap Preferred Stock Conversion Basis
PreferredStockConversionBasis
At the closing of the IPO, all of the outstanding shares of convertible preferred stock and redeemable convertible preferred stock were automatically converted into 32,972,793 shares of common stock.
CY2015Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
32972793
CY2015Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q1 rkda Inventory Raw Materials Current And Non Current
InventoryRawMaterialsCurrentAndNonCurrent
719000
CY2015Q4 rkda Inventory Raw Materials Current And Non Current
InventoryRawMaterialsCurrentAndNonCurrent
665000
CY2016Q1 rkda Inventory Finished Goods Current And Non Current
InventoryFinishedGoodsCurrentAndNonCurrent
1428000
CY2015Q4 rkda Inventory Finished Goods Current And Non Current
InventoryFinishedGoodsCurrentAndNonCurrent
1496000
CY2016Q1 rkda Inventory Current And Non Current Net
InventoryCurrentAndNonCurrentNet
2147000
CY2015Q4 rkda Inventory Current And Non Current Net
InventoryCurrentAndNonCurrentNet
2161000
CY2016Q1 rkda Inventory Reserves For Excess And Slow Moving Inventory
InventoryReservesForExcessAndSlowMovingInventory
2300000
CY2014Q4 rkda Inventory Reserves For Excess And Slow Moving Inventory
InventoryReservesForExcessAndSlowMovingInventory
2300000
CY2016Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
64081000
CY2016Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2016Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
34000
CY2016Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
64050000
CY2016Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2016Q1 rkda Maturity Of Long Term Investments
MaturityOfLongTermInvestments
2017
CY2016Q1 us-gaap Variable Interest Entity Terms Of Arrangements
VariableInterestEntityTermsOfArrangements
Both the Company and Bioceres incur expenses in support of specific activities agreed, as defined by joint work plans, which apply fair market value to each partner’s activities. Unequal contributions of services are equalized by the partners through cash payments. Verdeca is not the primary obligor for these activities performed by the Company or Bioceres. An agreement executed in conjunction with the formation of Verdeca specified that if Bioceres determines it requires cash to fund its contributed services (subject to certain annual limits), Bioceres, S.A. may elect to sell shares of its common stock to the Company for an amount not exceeding $5.0 million in the aggregate over a four-year period.
CY2016Q1 rkda Contributed Services Period
ContributedServicesPeriod
P4Y
us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
2000000
CY2014Q3 rkda Common Stock Shares Surrendered
CommonStockSharesSurrendered
1832
CY2016Q1 rkda Research Agreement Settled
ResearchAgreementSettled
205000
CY2016Q1 us-gaap Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
632
CY2016Q1 us-gaap Fair Value Hedges At Fair Value Net
FairValueHedgesAtFairValueNet
500000
CY2016Q1 us-gaap Cost Method Investments
CostMethodInvestments
0
CY2016Q1 us-gaap Variable Interest Entity Activity Between Vie And Entity Expense
VariableInterestEntityActivityBetweenVIEAndEntityExpense
40000
CY2015Q1 us-gaap Variable Interest Entity Activity Between Vie And Entity Expense
VariableInterestEntityActivityBetweenVIEAndEntityExpense
163000
CY2016Q1 us-gaap Long Term Debt
LongTermDebt
24978000
CY2015Q4 us-gaap Long Term Debt
LongTermDebt
24930000
CY2016Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
24978000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3427509
CY2016Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
29939
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
25775
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3371795
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
3142149
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.76
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.66
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.35
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.78
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
3.53
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3707000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2989000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
2989000
CY2016Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
511000
CY2016Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M26D
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.62
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2016Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2016Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.001
CY2015Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.041
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4708689
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38034345

Files In Submission

Name View Source Status
0001564590-16-018994-index-headers.html Edgar Link pending
0001564590-16-018994-index.html Edgar Link pending
0001564590-16-018994.txt Edgar Link pending
0001564590-16-018994-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gock5ghgwrdl000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rkda-10q_20160331.htm Edgar Link pending
rkda-20160331.xml Edgar Link completed
rkda-20160331.xsd Edgar Link pending
rkda-20160331_cal.xml Edgar Link unprocessable
rkda-20160331_def.xml Edgar Link unprocessable
rkda-20160331_lab.xml Edgar Link unprocessable
rkda-20160331_pre.xml Edgar Link unprocessable
rkda-ex1014_357.htm Edgar Link pending
rkda-ex311_7.htm Edgar Link pending
rkda-ex312_8.htm Edgar Link pending
rkda-ex321_9.htm Edgar Link pending
rkda-ex322_6.htm Edgar Link pending
Show.js Edgar Link pending